VBI Vaccines (OTCPK:VBIV.Q) - Prezzo delle azioni, notizie e analisi

VBIV.Q Panoramica delle azioni

VBI Vaccines Inc. è un'azienda biofarmaceutica in fase commerciale che sviluppa e vende vaccini per il trattamento dell'immuno-oncologia e delle malattie infettive. Maggiori dettagli

VBIV.Q analisi fondamentale
Punteggio fiocco di neve
Valutazione	2/6
Crescita futura	0/6
Prestazioni passate	0/6
Salute finanziaria	2/6
Dividendi	0/6

Analisi del rischio

Non ha una capitalizzazione di mercato significativa ( $14K )

Patrimonio netto negativo

Gli utili sono diminuiti del 17.4% all'anno negli ultimi 5 anni

Prezzo delle azioni altamente volatile negli ultimi 3 mesi

+ 1 più rischio

VBI Vaccines Inc. Concorrenti

Aditxt

NasdaqCM:ADTX

US$2.8m

TRACON Pharmaceuticals

OTCPK:TCON

US$100.5k

Genocea Biosciences

OTCPK:GNCA.Q

US$5.9k

Aridis Pharmaceuticals

OTCPK:ARDS

US$53.0

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per VBI Vaccines
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$0.0005
Massimo di 52 settimane	US$1.35
Minimo di 52 settimane	US$0.0002
Beta	2.22
1Variazione di 1 mese	0%
Variazione a 3 mesi	-97.37%
Variazione di 1 anno	-99.92%
3Variazione a 3 anni	-100.00%
Variazione a 5 anni	-100.00%
Variazione dall'IPO	-100.00%

Notizie e aggiornamenti recenti

Recent updates

VBI Vaccines down 10% on $300M mixed shelf offering; also ends two equity offerings

Aug 26

VBI Vaccines: Recent VBI-1901 Data Supports My Bull Thesis

Jun 17

Is VBI Vaccines (NASDAQ:VBIV) A Risky Investment?

Jun 09

Is VBI Vaccines (NASDAQ:VBIV) Using Debt Sensibly?

Jan 24

Rendimenti per gli azionisti

	VBIV.Q	US Biotechs	US Mercato
7D	0%	2.4%	2.2%
1Y	-99.9%	16.2%	31.7%

Ritorno vs Industria: VBIV.Q ha avuto una performance inferiore rispetto al US Biotechs che ha registrato un rendimento 16.2 % nell'ultimo anno.

Rendimento vs Mercato: VBIV.Q ha avuto una performance inferiore al mercato US che ha registrato un rendimento 31.7 % nell'ultimo anno.

Volatilità dei prezzi

Is VBIV.Q's price volatile compared to industry and market?
VBIV.Q volatility
VBIV.Q Average Weekly Movement	52.0%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.8%
10% least volatile stocks in US Market	3.1%

Prezzo delle azioni stabile: Il prezzo delle azioni di VBIV.Q è stato volatile negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale di VBIV.Q è aumentata da 36% a 52% nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
n/a	135	Jeff Baxter	www.vbivaccines.com

VBI Vaccines Inc. è un'azienda biofarmaceutica in fase commerciale che sviluppa e vende vaccini per il trattamento dell'immuno-oncologia e delle malattie infettive. Offre il vaccino contro l'epatite B (HBV) con i marchi PreHevbrio, PreHevbri e Sci-B-Vac. L'azienda sviluppa anche VBI-2601, un candidato immunoterapeutico a base di proteine per il trattamento dell'infezione cronica da HBV; VBI-1901, un candidato immunoterapeutico per il cancro del glioblastoma; VBI-1501, un candidato vaccino profilattico contro il citomegalovirus; e VBI-2501 per il trattamento del virus Zika.

VBI Vaccines Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di VBI Vaccines con la sua capitalizzazione di mercato?
VBIV.Q statistiche fondamentali
Capitalizzazione di mercato	US$14.34k
Guadagni(TTM)	-US$83.99m
Ricavi(TTM)	US$9.41m

0.0x

Rapporto P/S

0.0x

Rapporto P/E

VBIV.Q è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
VBIV.Q Conto economico (TTM)
Ricavi	US$9.41m
Costo del fatturato	US$11.67m
Profitto lordo	-US$2.26m
Altre spese	US$81.73m
Guadagni	-US$83.99m

Ultimi guadagni dichiarati

Mar 31, 2024

Prossima data di guadagno

n/a

Utile per azione (EPS)	-2.93
Margine lordo	-24.03%
Margine di profitto netto	-892.47%
Rapporto debito/patrimonio netto	-891.6%

Come si è comportato VBIV.Q nel lungo periodo?

Vedi performance storica e confronto

VBIV.Q Panoramica delle azioni

Analisi del rischio

VBI Vaccines Inc. Concorrenti

NasdaqCM:ADTX

US$2.8m

OTCPK:TCON

US$100.5k

OTCPK:GNCA.Q

US$5.9k

OTCPK:ARDS

US$53.0

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

VBI Vaccines Inc. Issues Voluntary Nationwide Recall of All PreHevbrio Vaccine Due to Discontinuation of Company Operations

The Nasdaq Stock Market to Delist Ordinary Shares of VBI Vaccines

VBI Vaccines Inc.(OTCPK:VBIV.Q) dropped from NASDAQ Composite Index

Nasdaq Determines to Delist Common Stock of VBI Vaccines in Accordance with Listing Rules 5101, 5110(b), and IM-5101-1

Nasdaq Provides Until July 8 Deadline to VBI Vaccines to Meet Minimum Stockholders' Equity Requirement

VBI Vaccines Inc. Announces Poster Presentation at 2024 ASCO Annual Meeting Highlighting New Interim Phase 2b Data from VBI-1901 in Recurrent Glioblastoma Patients

Recent updates

VBI Vaccines Inc. Issues Voluntary Nationwide Recall of All PreHevbrio Vaccine Due to Discontinuation of Company Operations

The Nasdaq Stock Market to Delist Ordinary Shares of VBI Vaccines

VBI Vaccines Inc.(OTCPK:VBIV.Q) dropped from NASDAQ Composite Index

Nasdaq Determines to Delist Common Stock of VBI Vaccines in Accordance with Listing Rules 5101, 5110(b), and IM-5101-1

Nasdaq Provides Until July 8 Deadline to VBI Vaccines to Meet Minimum Stockholders' Equity Requirement

VBI Vaccines Inc. Announces Poster Presentation at 2024 ASCO Annual Meeting Highlighting New Interim Phase 2b Data from VBI-1901 in Recurrent Glioblastoma Patients

VBI Vaccines Inc. has filed a Follow-on Equity Offering in the amount of $8.468289 million.

VBI Vaccines Inc. has completed a Follow-on Equity Offering in the amount of $2.000001 million.

VBI Vaccines Inc. has filed a Follow-on Equity Offering in the amount of $2.000001 million.

VBI Vaccines Inc. Presents Encouraging Early Tumor Response Data from Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma

VBI Vaccines Inc. announced delayed annual 10-K filing

VBI Vaccines Inc. Presents Additional Biomarker Data from Phase 1/2a Study of VBI-1901 in Recurrent GBM at the 2023 Society for Neuro-Oncology Annual Meeting

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

VBI Vaccines Inc. Receives a Letter from the Listing Qualifications Department of the Nasdaq Stock Market

VBI Vaccines Expands Proprietary Technology Platforms With Development of a Novel mRNA-Launched eVLP Vaccine Program

VBI Vaccines Inc. Announces Interim Data from the Phase 1 Clinical Study of its Multivalent Pan-Coronavirus Vaccine Candidate, VBI-2901

VBI Vaccines Inc. Announces Dosing of First Patients in Phase 2b Study of VBI-1901 in Recurrent GBM

Consensus revenue estimates increase by 291%, EPS downgraded

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

VBI Vaccines Inc. Announces PreHevbri® is Now Available in the Netherlands and Belgium for the Prevention of Hepatitis B in Adults

Consensus EPS estimates upgraded to US$4.46 loss

New major risk - Shareholder dilution

VBI Vaccines Inc. has completed a Follow-on Equity Offering in the amount of $18 million.

VBI Vaccines Inc. announced that it expects to receive $3 million in funding from Brii Biosciences Limited

VBI Vaccines Inc.(NasdaqCM:VBIV) dropped from Russell 2000 Dynamic Index

VBI Vaccines Inc. Announces Prehevbri® Is Now Available in the United Kingdom for the Prevention of Hepatitis B in Adults

Now 21% undervalued after recent price drop

Consensus revenue estimates decrease by 38%, EPS upgraded

Price target decreased by 45% to US$33.00

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates fall by 1,377%

Insufficient new directors

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

No longer forecast to breakeven

VBI Vaccines Announces Presentation of Interim Phase 2 Data Evaluating Combination of VBI-2601 (BRII-179) and BRII-835 for the Treatment of Chronic Hepatitis B

VBI Vaccines Inc. Announces Health Canada Approval for Prehevbrio™ for Prevention of Hepatitis B in Adults

No longer forecast to breakeven

VBI Vaccines Presents Additional Phase 1/2A Data from VBI-1901 in Recurrent GBM At the 2022 Society for Neuro-Oncology Annual Meeting

Consensus forecasts updated

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

VBI Vaccines Announces Initiation of Phase 1 Study of Multivalent Coronavirus Vaccine Candidate, VBI-2901

VBI Vaccines: Recent Updates Have Fortified My Long-Term Outlook

VBI Vaccines Inc. Announces Presentation of Physician-Initiated Compassionate Use Data of Its 3-Antigen Hepatitis B Vaccine At the 2022 International HBV Meeting

VBI Vaccines gets up to $100M debt funding from K2 HealthVentures

VBI Vaccines Inc. Announces the Resignation of Linda C. Bain from the Board of Directors

Valneva, VBI Vaccines in pact to launch Hep B vaccine in Europe

VBI Vaccines down 10% on $300M mixed shelf offering; also ends two equity offerings

Consensus revenue estimates fall by 32%

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

VBI Vaccines Inc. Announces Appointment of John Dillman as Chief Commercial Officer

VBI Vaccines Receives Non-Compliance Notice from Nasdaq

VBI Vaccines Announces New Long-Term Follow-Up Clinical Data for Its 3-Antigen Adult Hepatitis B Vaccine

VBI Vaccines Inc. Receives U.S. Food and Drug Administration Orphan Drug Designation for VBI-1901 for the Treatment of Glioblastoma

VBI Vaccines: Recent VBI-1901 Data Supports My Bull Thesis

Is VBI Vaccines (NASDAQ:VBIV) A Risky Investment?

VBI Vaccines Inc. Announces Updated Phase 2A Tumor Response and Overall Survival Data for VBI-1901

VBI Vaccines Inc. Announces UK MHRA Marketing Authorisation for Prehevbri

Consensus forecasts updated

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat